Business Wire

Gen Re and PAI Health Take Strategic Partnership to Next Level

Share

Decades of evidence have proven cardiorespiratory fitness to be a leading predictor of longevity and future health. Yet it is one that has been largely overlooked within insurance customer health profiles. With the signing of the exclusive agreement between leading global reinsurer, Gen Re, and health technology software company, PAI Health, this is set to change.

PAI Health is known for its innovation in biometric sensing and algorithm development with unique data insights rooted in cardiorespiratory fitness. The company’s digital services are based on published research that has demonstrated the effectiveness of the heart rate-based metric called Personal Activity Intelligence (PAI) in recommending personalized activity levels for optimal mortality risk reduction from cardiovascular disease and other lifestyle diseases.

Over the past 18 months, Gen Re and PAI Health have been working together to tailor the PAI proposition for the insurance sector. Together, they have now begun showcasing its potential to Gen Re’s clients around the world, with a view to using PAI’s potential to drive customer engagement and explore new ways of assessing risk.

Commenting on the agreement, Winfried Heinen, Head of Gen Re Life/Health International, said: “We meet many insurtech companies with promising ideas but PAI Health stood out from the start due to the scientific rigour behind their solution. We have no doubt about the value PAI holds for the insurance community, both in terms of acquisition and engagement, and ultimately helping consumers lead longer and healthier lives.”

Vincent DeMarco, Head of Gen Re’s North American Life/Health Division, added: “The signing of this agreement demonstrates our mutual commitment to bringing PAI Health’s pioneering mHealth technology to insurance. We look forward to working closely with them to build on the momentum already created.”

Speaking on behalf of PAI Health, Chief Commercial Officer Sally Powell said: “PAI Health’s global strategic partnership with Gen Re comes at the right time as the insurance industry is being challenged by customers to provide digital health solutions that are highly personalised and provide health protection day to day. Gen Re’s global presence combined with our unique solutions makes us ideal partners to co-develop digital insurance solutions that provide significant value to insurers and their policyholders.”

  • Hear more about the science behind PAI from inventor Ulrik Wisløff, Professor at NTNU and Head of the Cardiac Exercise Research Group, in conversation with Gen Re’s Ross Campbell. Link to 5 min video

PAI Health is one of a selection of hand-picked insurtech companies Gen Re is working with to develop insurance products and solutions that meet the needs and expectations of consumers in the digital age. Contact us to find out more about our digital activities and to arrange an introduction.

About Gen Re

Gen Re delivers reinsurance solutions to the Life/Health and Property/Casualty insurance industries. We work closely with our clients to understand their strategic and operational goals, offering a wide range of products, tools and resources that aim to promote our clients’ ongoing growth and success.

Gen Re is a member of the Berkshire Hathaway family of companies and has earned superior financial strength ratings from each of the major rating agencies. We take our commitments very seriously. With $14.4 billion in capital and $9.7 billion in premiums, we only make promises we can keep. www.genre.com

About PAI Health

PAI Health is a health technology company that offers unique data insights rooted in the proven science of cardiorespiratory fitness. The company’s suite of digital tools help insurers increase engagement, drive new customer acquisition and reduce costs. PAI (Personal Activity Intelligence) is the first scientifically validated and published score that prescribes a personalised level of activity to optimize an individual’s cardiorespiratory fitness to reduce the risk of cardiovascular and other lifestyle diseases. www.paihealth.com

Contact information

Media Contact:
Sabine Denné, Head of Global Marketing & Client Communications, email: denne@genre.com

Product Contacts:
International: Ross Campbell, Life/Health Chief Underwriter R&D, email: ross_campbell@genre.com

North America: Ammon Dixon, Life/Health Strategic Initiative Projects Leader, email: ammon.dixon@genre.com

PAI Health Contact:
Tricia Burton, VP, Marketing, email: tricia.burton@paihealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 22:00:00 EETPress release

Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 18:20:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma

Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 18:18:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 17:30:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu

Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 21:07:00 EETPress release

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer

BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 16:00:00 EETPress release

BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom